Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Real-world evidence of venetoclax vs ibrutinib vs idelalisib

Anthony Mato • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Idelalisib Venetoclax

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the first real-world evidence of venetoclax vs ibrutinib vs idelalsib in chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Anthony Mato

The importance of genomic testing in CLL prognosis 1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
Time-limited vs continuous therapy in CLL treatment 1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
Updates on non-covalent BTK inhibitors and their place in CLL treatment 2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
Pirtobrutinib resistance in CLL: early findings 1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals